Sixfold raises $10.5M to improve RNA delivery to untargeted tissues
Sixfold - 07-Dec-2020Using machine learning, they plan to expand RNA therapy to treat various diseases
Join the club for FREE to access the whole archive and other member benefits.
Programmable drug delivery systems with a current focus on siRNA and mRNA
In 2017 we saw an opportunity that few wanted to solve – delivery. Today, RNA delivery is central to unlocking continued expansion in one of the fastest growing sectors in biotech. We’re comfortable with unconventional and have conviction in our execution.
Our pioneering spirit is reflected in our origins. We weren’t born out of an academic lab, encumbered by dogma, bureaucracy and university IP restrictions. Sixfold was started from scratch after a chance encounter between oncologist Dr. Anna Perdrix Rosell and plant scientist Dr. George Foot, brought two opposite, yet complementary, perspectives in RNA together.
Now a team of over 20 coders, chemists, biologists and automation engineers, Sixfold is redefining what was thought to be possible in RNA with our radically new approach to delivery. We’re a melting pot of diverse perspectives, collaboration and a desire to solve the hardest problems.
Visit website: https://www.sixfold.bio/
Details last updated 17-Mar-2024
Using machine learning, they plan to expand RNA therapy to treat various diseases